ECON 2P23 Lecture Notes - Lecture 8: Hastings College, Abbvie Inc., Adalimumab
3 Mar 2018
School
Department
Course
Professor
Document Summary
Drugmakers are using a variety of strategies to extend the exclusivity period of their wares, keeping less expensive alternatives away from patients. Bloomberg, by cynthia koons /robert langreth / december 20, 2017. Bo(cid:271) kelse(cid:455) (cid:272)a(cid:374)(cid:859)t affo(cid:396)d a (cid:272)a(cid:374)(cid:272)e(cid:396) drug that could save his life. The retired firefighter, 53, needs revlimid to stay healthy. Drugmakers typically have exclusive rights to sell brand-name medicines for 12 or 13 years. After that, cheaper copycats can hit the market. The e(cid:454)pi(cid:396)atio(cid:374) date fo(cid:396) the (cid:373)ai(cid:374) e(cid:448)li(cid:373)id pate(cid:374)t (cid:449)ill (cid:271)e (cid:1006)(cid:1004)(cid:1005)(cid:1013). But celge(cid:374)e(cid:859)s (cid:271)usi(cid:374)ess ta(cid:272)ti(cid:272)s, also used by other drugmakers, could allow the company to put off unrestricted competition from generics until: that would cost americans an extra billion just for revlimid, according to i-mak, a consumer advocate. Scott gottlieb, commissioner of the u. s. food and drug administration, is so fed up with a range of diffe(cid:396)e(cid:374)t d(cid:396)ug(cid:373)ake(cid:396)s(cid:859) (cid:373)a(cid:272)hi(cid:374)atio(cid:374)s he deli(cid:448)e(cid:396)ed a sha(cid:396)p (cid:396)e(cid:271)uke last (cid:373)o(cid:374)th: (cid:862)e(cid:374)d the she(cid:374)a(cid:374)iga(cid:374)s. (cid:863)
